Bausch+Lomb Results Presentation Deck

Reported Revenue Trailing Quarters by Segment Bausch + Lomb Vision Care² Contact Lens Consumer Total Revenue Surgical¹ Implantables Equipment Consumables Total Revenue Ophthalmic Pharmaceuticals ² Total Revenue BAUSCH + LOMB 1Q23 $226M $361M $587M $44M $44M $95M $183 M $161 M 4Q22 $219M $407M $626M $49M $45M $94M $188M $182M 3Q22 $222M $376M $598M $45M $42M $85M $172M $172M 2Q22 $213M $376M $589M $49M $42M $93M $184M $168M 1Q22 $215M $345M $560M $45M $42M $87M $174M $155M 1. As of the first quarter of 2023, certain products were recategorized across the consumables, im pantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis. Effective in the first quarter of 2023, certain products historically included in the reported results of the Ophthalmic Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Ophthalmic Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure. 24

View entire presentation